Patent 10,730,895 (US) scope and claims: what Formula (I-b) compound claims cover, and how broad is the US patent estate
US Patent 10,730,895 is a compound-claims patent with an express structure-based claim format tied to “Formula (I-b)” (Claim 1: “A compound corresponding in structure to Formula (I-b): or a pharmaceutically acceptable salt thereof.”). The practical scope is determined by (i) what Formula (I-b) defines in the specification drawings/description and (ii) how dependent claims, examples, and “corresponding in structure” language are used to fence in chemical variants, salts, stereochemistry, and ring substituent ranges.
Because only Claim 1 is provided and Formula (I-b) itself is not included, a complete, accurate, claim-by-claim scope map of coverage boundaries (substitution limits, allowed substituents, stereochemical coverage, and salt classes) cannot be produced from the supplied information.
What does US patent 10,730,895 claim with “corresponding in structure to Formula (I-b)”
How “structure to Formula (I-b)” constrains chemical coverage
The claim is not a genus defined by functional language (eg, “inhibits X”), but a structural genus defined by a specific scaffold and substitution pattern. In such claims, the coverage generally tracks these elements:
- Core scaffold defined by Formula (I-b)
- Allowed substituents and positions within Formula (I-b)
- Valid stereochemical definitions, if included in Formula (I-b)
- Permitted “pharmaceutically acceptable salt” forms
A court typically reads “corresponding in structure” as requiring structural correspondence to the drawn/defined scaffold and variable groups. That usually narrows the set to compounds that fall within the exact structural parameters set out for Formula (I-b), including any enumerated or defined ranges for substituents.
What is implicitly included: salts
Claim 1 explicitly includes “pharmaceutically acceptable salt[s].” That normally means the claim covers salts of the claimed free base/acid form, as supported by the specification. Salt coverage can extend to common pharmaceutical salts if they are recognized as pharmaceutically acceptable and supported by the disclosure.
What is not determinable from Claim 1 alone
Claim 1, standing alone, does not reveal:
- Whether Formula (I-b) is a single chemical structure (single compound) or a variable-parameter genus
- Which substituent variables are defined as alternatives (eg, “R1 is …”)
- Whether specific stereoisomers are required or merely optional
- Whether tautomeric forms, hydrates, or polymorphs are claimed (polymorphs are typically formulation or solid-state claims, not usually captured by a “compound corresponding to Formula (I-b)” unless the salt/hydrate type is embedded in the formula)
How broad is Claim 1 coverage for Formula (I-b) compounds in US patent 10,730,895
Breadth drivers
For structure-defined compound claims, breadth depends on how Formula (I-b) is drafted. Common breadth drivers include:
- Wide variable ranges (many substituent options, many positions)
- Broad generic definitions for R groups
- Lack of restrictive exemplars or narrow preferred embodiments
- Inclusion of tautomers/stereochemicals within the formula
Breadth limiters
The following features often limit practical coverage even when the claim reads broadly:
- Formula variables that actually encode narrow sets
- “Corresponding in structure” tied to specific substitution positions
- Explicit exclusions in the definition of Formula (I-b)
- Dependence on a particular stereochemistry or conformer set within the formula
- Salt limitation via the specification’s described acids/bases
Litigation-relevant consequence
Compound claim construction will map Formula (I-b) directly to accused structures. If Formula (I-b) includes multiple variables, claim scope can become a contested question of whether the accused compound “corresponds” to the defined variable substitution. That typically becomes a Markman-style interpretation of the formula’s variable definitions and how they map to structure.
Do dependent claims in US 10,730,895 narrow Formula (I-b) coverage beyond Claim 1
Typical patterns in structure-based compound patents
Even when Claim 1 is a broad genus, dependent claims often narrow to:
- Specific compounds within Formula (I-b) (examples)
- Specific salts (enumerated)
- Specific stereoisomers (eg, (R)- or (S)-)
- Preferred substituent sets (preferred embodiments)
- Specific methods of preparation or intermediates
What cannot be derived from the provided excerpt
Without the dependent claim list and Formula (I-b) definition, it is not possible to quantify the number of narrower claim fallbacks or to determine whether the patent includes:
- Separate Markush groups that reduce ambiguity
- Any method-of-use claims (Claim 1 as provided is purely compound)
- Any formulation claims that would create product-level barriers
What patent estate surrounds US 10,730,895: is it a continuation, division, or reissue likely to extend exclusivity
Why this matters
If US 10,730,895 is a continuation or division of earlier applications, the practical landscape often includes:
- Earlier priority application scope that affects whether later entrants can design around
- Filing date and priority date determining the effective “family” boundary for related claims
- Overlapping expiration windows across the family
Non-derivable from Claim 1 excerpt
No application number, patent family members, priority dates, or continuation data are provided. A family-level landscape cannot be built accurately from Claim 1 alone.
What does the “pharmaceutically acceptable salt” phrase do to infringement risk for competitors
Two common infringement scenarios
- Competitor sells the free base only but the accused infringement theory asserts salt formation in vivo or during manufacturing.
- Competitor sells a specific salt form that is within the salts supported/covered.
Claim scope mechanics
Salt coverage depends on whether the claim construction includes:
- Any pharmaceutically acceptable salt for the compound, or
- Only those salts described in the specification with support for “pharmaceutically acceptable.”
Since Claim 1 explicitly includes salts, infringement risk for salt variants is generally higher than if salts were excluded, but the exact reach depends on what the specification enables and how the claims are construed.
How does US patent 10,730,895 affect generic or biosimilar design-around strategies
Design-around levers for compound claims
For a structure-defined scaffold, common design-around strategies include:
- Substituting at a position that is variable in Formula (I-b) but selecting a value outside the allowed definition
- Altering the core scaffold so the compound is no longer “corresponding in structure” to Formula (I-b)
- Choosing a different salt form does not fully avoid infringement if the API itself matches the scaffold and the salt is within the salt definition
Key commercial risk
If the marketed API is within Formula (I-b), the compound claim can be a direct barrier to generic ANDA approval if no carve-out exists in the patent family.
What cannot be determined
No information is provided linking the patent to:
- a particular drug product name,
- an active ingredient identity,
- an Orange Book listing,
- or a known therapeutic target.
Without that, it is not possible to map the patent’s real-world enforcement posture or the likelihood that competitors’ products fall within its structure.
What Orange Book status is likely for US 10,730,895 and what generic entry risks exist
Claim type versus Orange Book listing
Compound claims that cover the active ingredient (or a salt form) are commonly listed in the Orange Book for an ANDA drug if the active ingredient matches the claim scope.
Non-derivable status
Orange Book status, listed drug products, and exclusivity mapping require the listed application numbers and drug identifiers. Those are not provided.
What Paragraph IV challenges or settlements are triggered by US 10,730,895
Typical triggers
A Paragraph IV notice is typically linked to:
- an Orange Book listed patent, and
- an ANDA drug that includes an identical or bioequivalent active ingredient.
Non-derivable litigation map
No litigation or settlement records are provided, and no drug identifier is provided. A litigation landscape cannot be built from Claim 1 alone.
How strong is the patent estate for US 10,730,895 based on the limited claim excerpt
Strength factors for structure-based compound claims
- Structural specificity can improve enforceability because “correspondence” limits capture to defined scaffolds.
- Validity challenges often focus on whether the scaffold was disclosed in earlier patents/publications and whether the claimed variants are obvious.
- Salt inclusion can broaden enforceability against alternative salt forms.
What cannot be evaluated without the full document
Assessing strength requires:
- the specification’s disclosure and examples,
- the breadth of variable definitions in Formula (I-b),
- the prosecution history,
- citation list and legal status,
- and the exact claim set.
Those materials are not included.
Key takeaways
- US 10,730,895 Claim 1 is a structural compound claim covering “a compound corresponding in structure to Formula (I-b)” and its pharmaceutically acceptable salts.
- The practical scope is controlled by the definition of Formula (I-b) in the patent specification: permitted substituents, variable ranges, stereochemistry, and the scaffold boundary.
- Salt language expands coverage to pharmaceutically acceptable salts of the claimed scaffold.
- A complete landscape (family members, expiration timeline, Orange Book listing, Paragraph IV and settlements, and generic entry risk) cannot be determined from the Claim 1 excerpt alone because the drug identity, application data, and Formula (I-b) definition are missing.
FAQs
- Does “corresponding in structure” require identical substitution patterns to Formula (I-b)?
- Are all salt forms covered under “pharmaceutically acceptable salt” in US 10,730,895 Claim 1?
- How do dependent claims typically narrow a Formula-based compound genus in US patents like 10,730,895?
- Can a competitor avoid infringement by changing stereochemistry while keeping the same scaffold?
- What evidence most often drives claim construction for structure-defined formula claims in the US?
References (APA)
- United States Patent 10,730,895.
